The STEP-HFpEF (Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity) and STEP-HFpEF-DM (Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes) trials investigated the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide in patients with obesity-related HFpEF, with and without diabetes. The gene discussed is GLP1R; the disease is obesity disorder.